{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:44:20Z","timestamp":1786963460162,"version":"build-2736575974"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.00593","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T05:18:11Z","timestamp":1593148691000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Genotype-Phenotype Correlations and Characterization of Medication Use in Inherited Myotonic Disorders"],"prefix":"10.3389","volume":"11","author":[{"given":"Alayne P.","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Roggenbuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. David","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.nurt.2007.01.012","article-title":"The non-dystrophic myotonias","volume":"4","author":"Heatwole","year":"2007","journal-title":"Neurotherapeutics."},{"key":"B2","doi-asserted-by":"publisher","first-page":"685328","DOI":"10.1155\/2011\/685328","article-title":"Physiology and pathophysiology of CLC-1: mechanisms of a chloride channel disease, myotonia","volume":"2011","author":"Tang","year":"2011","journal-title":"J Biomed Biotechnol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/mus.20923","article-title":"Differential diagnosis of myotonic disorders","volume":"37","author":"Timothy","year":"2008","journal-title":"Muscle Nerve"},{"key":"B4","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/ejhg.2008.39","article-title":"In tandem analysis of CLCN1 and SCN4A greatly enhances mutation detection in families with non-dystrophic myotonia","volume":"16","author":"Trip","year":"2008","journal-title":"Eur J Hum Gene."},{"key":"B5","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/mus.23683","article-title":"The diagnosis and treatment of myotonic disorders","volume":"47","author":"Heatwole","year":"2013","journal-title":"Muscle Nerve."},{"key":"B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/brain\/awp294","article-title":"The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment","volume":"133","author":"Matthews","year":"2010","journal-title":"Brain."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1212\/WNL.0b013e31828cf8d0","article-title":"Prevalence study of genetically defined skeletal muscle channelopathies in England","volume":"80","author":"Horga","year":"2013","journal-title":"Neurology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1097-2765(02)00563-4","article-title":"Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy","volume":"10","author":"Mankodi","year":"2002","journal-title":"Mol Cell."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/1097-4598(200012)23:12<1789::AID-MUS2>3.0.CO;2-4","article-title":"Meola G. Clinical and genetic heterogeneity in myotonic dystrophies","volume":"23","author":"Meola","year":"2000","journal-title":"Muscle Nerve."},{"key":"B10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.ncl.2014.04.011","article-title":"Myotonic Dystrophy","volume":"32","author":"Thornton","year":"2014","journal-title":"Neurologic Clinics."},{"key":"B11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/WCO.0000000000000128","article-title":"Myotonic dystrophy: diagnosis, management and new therapies","volume":"27","author":"Turner","year":"2014","journal-title":"Curr Opin Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/00019052-199510000-00014","article-title":"Hereditary nondystrophic myotonias and periodic paralyses","volume":"8","author":"Lehmann-Horn","year":"1995","journal-title":"Curr Opin Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10072-016-2805-5","article-title":"Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects","volume":"38","author":"Meola","year":"2017","journal-title":"Neurol Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.expneurol.2013.12.005","article-title":"Nondystrophic myotonia: challenges and future directions","volume":"253","author":"Trivedi","year":"2014","journal-title":"Exp Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fphar.2015.00314","article-title":"Physiological and Pathophysiological Insights of Nav1.4 and Nav1.5 Comparison","volume":"6","author":"Loussouarn","year":"2016","journal-title":"Front Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/164_2017_52","article-title":"Sodium channelopathies of skeletal muscle. In Chahine M, ed. Voltage-Gated Sodium Channels: Structure, Function and Channelopathies","author":"Cannon","year":"2017","journal-title":"Vol. 246"},{"key":"B17","doi-asserted-by":"publisher","first-page":"27822","DOI":"10.1038\/s41598-018-27822-2","article-title":"Hypokalaemic periodic paralysis and myotonia in a patient with homozygous mutation p","volume":"8","author":"Luo","year":"2018","journal-title":". Sci Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1212\/WNL.0b013e3181dc1a3a","article-title":"Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1(LOE Classification)","volume":"74","author":"Logigian","year":"2010","journal-title":"Neurology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1001\/jama.2012.12607","article-title":"Mexiletine for symptoms and signs of myotonia in non-dystrophic myotonia: a randomized controlled trial","volume":"308","author":"Statland","year":"2012","journal-title":"JAMA."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1001\/jama.2018.18020","article-title":"Effect of mexiletine on muscle stiffness in patients with nondystrophic myotonia evaluated using aggregated N-of-1 trials","volume":"320","author":"Stunnenberg","year":"2018","journal-title":"JAMA."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1093\/brain\/awx192","article-title":"The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study","volume":"140","author":"Andersen","year":"2017","journal-title":"Brain."},{"key":"B22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1136\/jnnp.2008.162396","article-title":"Redefining the clinical phenotypes of non-dystrophic myotonic syndromes","volume":"80","author":"Trip","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1093\/brain\/awt133","article-title":"Non-dystrophic myotonia: prospective study of objective and patient reported outcomes","volume":"136","author":"Trivedi","year":"2013","journal-title":"Brain."},{"key":"B24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1212\/01.wnl.0000287069.21162.94","article-title":"What causes paramyotonia in the United Kingdom? Common and new SCN4A mutations revealed","volume":"70","author":"Matthews","year":"2008","journal-title":"Neurology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.23937\/2378-3001\/1\/1\/1009","article-title":"The character and frequency of muscular pain in myotonic dystrophy and their relationship to myotonia","volume":"1","author":"Parmova","year":"2014","journal-title":"Int J Neurol Neurother."},{"key":"B26","first-page":"126","article-title":"Multidimensional aspects of pain in myotonic dystrophies","volume":"34","author":"Peric","year":"2015","journal-title":"Acta Myol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00593\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T05:18:13Z","timestamp":1593148693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00593\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":26,"alternative-id":["10.3389\/fneur.2020.00593"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.00593","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]},"article-number":"593"}}